Equities research analysts forecast that Cigna Holding Co (NYSE:CI) will report earnings per share (EPS) of $3.77 for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Cigna’s earnings. The lowest EPS estimate is $3.47 and the highest is $4.15. Cigna posted earnings per share of $4.11 during the same quarter last year, which suggests a negative year over year growth rate of 8.3%. The company is scheduled to announce its next earnings report on Thursday, May 2nd.
On average, analysts expect that Cigna will report full-year earnings of $16.47 per share for the current fiscal year, with EPS estimates ranging from $16.09 to $17.06. For the next financial year, analysts forecast that the company will report earnings of $18.51 per share, with EPS estimates ranging from $18.30 to $18.69. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Cigna.
Cigna (NYSE:CI) last issued its earnings results on Friday, February 1st. The health services provider reported $2.46 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.53 by ($0.07). The company had revenue of $13.75 billion for the quarter, compared to analysts’ expectations of $11.38 billion. Cigna had a net margin of 5.42% and a return on equity of 16.64%. The firm’s revenue for the quarter was up 29.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.94 earnings per share.
NYSE:CI opened at $182.89 on Tuesday. The stock has a market capitalization of $44.16 billion, a P/E ratio of 12.86, a price-to-earnings-growth ratio of 0.90 and a beta of 0.72. Cigna has a 1-year low of $163.02 and a 1-year high of $226.60. The company has a quick ratio of 0.98, a current ratio of 0.42 and a debt-to-equity ratio of 0.96.
In related news, Director William D. Zollars sold 201 shares of the firm’s stock in a transaction that occurred on Friday, December 14th. The stock was sold at an average price of $210.84, for a total value of $42,378.84. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director John Partridge sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 7th. The stock was sold at an average price of $184.43, for a total value of $184,430.00. The disclosure for this sale can be found here. Corporate insiders own 1.10% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. 1 North Wealth Services LLC acquired a new position in shares of Cigna during the 4th quarter valued at $25,000. Private Ocean LLC acquired a new stake in shares of Cigna in the fourth quarter worth $26,000. Delta Asset Management LLC TN acquired a new stake in shares of Cigna in the fourth quarter worth $28,000. Litman Gregory Asset Management LLC acquired a new stake in shares of Cigna in the fourth quarter worth $30,000. Finally, Valeo Financial Advisors LLC boosted its position in Cigna by 216.4% during the fourth quarter. Valeo Financial Advisors LLC now owns 174 shares of the health services provider’s stock valued at $33,000 after purchasing an additional 119 shares during the last quarter. Hedge funds and other institutional investors own 93.44% of the company’s stock.
Cigna Company Profile
Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers.
Read More: How to invest in blue-chip stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.